biote (BTMD) Projected to Post Quarterly Earnings on Wednesday

biote (NASDAQ:BTMD) is expected to announce its Q3 2026 results after the market closes on Wednesday, November 4th. Analysts expect the company to announce earnings of ($0.05) per share and revenue of $44.01 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Wednesday, November 4, 2026 at 5:00 PM ET.

biote (NASDAQ:BTMD) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.26). The business had revenue of $44.23 million during the quarter, compared to analyst estimates of $46.12 million. On average, analysts expect biote to post $0.03 EPS for the current fiscal year and $0.17 EPS for the next fiscal year.

biote Stock Performance

NASDAQ BTMD opened at $1.18 on Wednesday. The stock has a market cap of $42.39 million, a P/E ratio of 10.73 and a beta of 1.69. biote has a fifty-two week low of $1.00 and a fifty-two week high of $2.98. The stock has a 50 day simple moving average of $1.31 and a two-hundred day simple moving average of $1.85.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. B. Riley Financial dropped their price target on biote from $2.00 to $1.50 and set a “neutral” rating for the company in a research note on Monday, August 10th. TD Cowen reduced their price objective on shares of biote from $2.50 to $2.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Finally, Weiss Ratings lowered shares of biote from a “sell (d+)” rating to a “sell (d)” rating in a report on Thursday, August 13th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $2.50.

Insider Buying and Selling at biote

In other news, Chairman Marc Beer bought 115,950 shares of biote stock in a transaction on Monday, August 10th. The shares were purchased at an average price of $1.53 per share, for a total transaction of $177,403.50. Following the acquisition, the chairman owned 223,744 shares of the company’s stock, valued at approximately $342,328.32. The trade was a 107.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 32.40% of the company’s stock.

biote Company Profile

Biote Inc (NASDAQ: BTMD) is a healthcare company focused on hormone optimization and personalized care. Through its provider-enabled platform, the company supports physicians and other healthcare professionals who offer bioidentical hormone replacement therapy and related wellness services.

The company’s offerings include the Biote Method, a hormone pellet therapy program designed for eligible men and women, as well as nutritional supplements, patient education, clinical training, and practice-management support.